Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema

Table 2 Mean CMT and CDVA of three groups at baseline and follow up visits

Variables		Groups			Total P-value	P-value (Group 1 vs. 2)	P-value (Group 1 vs. 3)	P-value (Group 2 vs. 3)
Variables		IVB + IFN Drop (Group 1)	IVB + IFN Injection (Group 2)	IVB (Group 3)	Total P-value	P-value (Group 1 vs. 2)	P-value (Group 1 vs. 3)	P-value (Group 2 vs. 3)
CMT (microns)	Baseline	566 ± 202	560 ± 238	543 ± 179	0.907^†	0.995	0.960	0.999
	1st month	499 ± 217	420 ± 122	494 ± 122	0.068*	0.137	0.999	0.104
	Change	− 67 ± 157	− 140 ± 194	− 49 ± 104
	P-within^§	0.073	0.020	0.030
	2nd month	461 ± 166	482 ± 171	489 ± 120	0.316*	0.925	0.409	0.999
	Change	− 105 ± 151	− 78 ± 115	− 54 ± 90
	P-within^§	0.006	0.091	0.006
	3rd month	517 ± 214	443 ± 128	507 ± 128	0.085*	0.145	0.999	0.151
	Change	− 49 ± 173	− 117 ± 213	− 36 ± 86
	P-within^§	0.239	0.025	0.054
CDVA (LogMAR)	Baseline CDVA	0.91 ± 0.56	0.71 ± 0.43	0.76 ± 0.49	0.671^†	0.815	0.822	0.999
	1st month	0.80 ± 0.49	0.61 ± 0.31	0.69 ± 0.32	0.819*	0.488	0.805	0.886
	Change	− 0.11 ± 0.41	− 0.10 ± 0.39	− 0.07 ± 0.26
	P-within^‡	0.145	0.260	0.216
	2nd month	0.68 ± 0.40	0.76 ± 0.41	0.76 ± 0.41	0.739*	0.898	0.872	0.999
	Change	− 0.23 ± 0.39	0.05 ± 0.26	0.01 ± 0.18
	P-within^‡	0.003	0.496	0.802
	3rd month	0.71 ± 0.46	0.63 ± 0.37	0.75 ± 0.38	0.769*	0.956	0.994	0.850
	Change	− 0.20 ± 0.43	− 0.08 ± 0.25	− 0.01 ± 0.13
	P-within^‡	0.010	0.308	0.723

Bold values denote statistical significance at the p value < 0.05 level
^†Based on ANOVA, between-group comparison adjusted by Bonferroni method
^§Based on linear mixed model, comparison with baseline value, adjusted for the multiple comparisons by Bonferroni method
^*Based on ANCOVA, adjusted for the baseline value, between-group comparison adjusted by Bonferroni method
^‡ Based on Wilcoxon signed rank test, compared with baseline value

ISSN: 2056-9920